Largest ARCA Biotechnology Companies By Total Asset

Total Asset
Total AssetEfficiencyMarket RiskExp Return
1AMGN Amgen Inc
97.15 B
(0.15)
 1.69 
(0.25)
2GILD Gilead Sciences
62.12 B
 0.19 
 1.42 
 0.27 
3GMAB Genmab AS
35.29 B
(0.28)
 1.52 
(0.42)
4REGN Regeneron Pharmaceuticals
33.08 B
(0.40)
 1.73 
(0.70)
5BIIB Biogen Inc
26.84 B
(0.29)
 1.33 
(0.38)
6VRTX Vertex Pharmaceuticals
22.73 B
(0.05)
 1.76 
(0.09)
7MRNA Moderna
18.43 B
(0.23)
 3.57 
(0.84)
8ILMN Illumina
10.11 B
 0.08 
 2.30 
 0.18 
9UTHR United Therapeutics
7.17 B
 0.04 
 1.72 
 0.08 
10BMRN Biomarin Pharmaceutical
6.84 B
(0.19)
 2.57 
(0.48)
11INCY Incyte
6.78 B
 0.10 
 2.50 
 0.25 
12EXAS EXACT Sciences
6.47 B
 0.02 
 4.28 
 0.10 
13BGNE BeiGene
5.81 B
 0.06 
 2.60 
 0.15 
14WAT Waters
4.63 B
 0.07 
 2.97 
 0.21 
15ARGX argenx NV ADR
4.54 B
 0.15 
 2.01 
 0.29 
16BRKR Bruker
4.25 B
(0.07)
 2.69 
(0.19)
17ALNY Alnylam Pharmaceuticals
3.83 B
(0.01)
 2.19 
(0.03)
18MTD Mettler Toledo International
3.36 B
(0.11)
 1.97 
(0.21)
19NBIX Neurocrine Biosciences
3.25 B
 0.00 
 1.69 
 0.01 
20EXEL Exelixis
2.94 B
 0.22 
 2.40 
 0.54 
The analysis above is based on a 90-day investment horizon and a default level of risk. Use the Portfolio Analyzer to fine-tune all your assumptions. Check your current assumptions here.
Total Asset is everything that a business owns. It is the sum of current and long-term assets owned by a firm at a given time. These assets are listed on a balance sheet and typically valued based on their purchasing prices, not the current market value. Total Asset is typically divided on the balance sheet on current asset and long-term asset. Long-term is the value of company property and other capital assets that are expected to be useable for more than one year. Long term assets are reported net of depreciation. On the other hand current assets are assets that are expected to be sold or converted to cash as part of normal business operation.